|1.||Chandan, B K: 3 articles (05/2007 - 06/2001)|
|2.||Singh, B: 3 articles (05/2007 - 06/2001)|
|3.||Saxena, A K: 3 articles (05/2007 - 06/2001)|
|4.||Sahabutdinov, Marat: 1 article (11/2015)|
|5.||Golodnii, Svetoslav: 1 article (11/2015)|
|6.||Manukhina, Eugenia: 1 article (11/2015)|
|7.||Tseylikman, Vadim: 1 article (11/2015)|
|8.||Tseylikman, David: 1 article (11/2015)|
|9.||Lapshin, Maxim: 1 article (11/2015)|
|10.||Downey, H Fred: 1 article (11/2015)|
12/01/1969 - "Experimental studies on the model of hexobarbital-narcosis in rat]."
08/01/1955 - "[Study on pathological electric activity of the brain in hexobarbital narcosis of epileptics]."
07/15/2009 - "Pretreatment with Sida acuta extract significantly shortened the duration of hexobarbitone-induced narcosis in mice indicating its hepatoprotective potential. "
05/01/1995 - "[Daily dynamics of the duration of hexenal narcosis in experimental hepatosis]."
02/01/1990 - "However, even with 10(7) U/kg (s.c.), no effect was found in general behavior, rotarod performance and hexobarbital narcosis in mice. "
07/01/1988 - "1. Central nervous system: MDP-Lys(L18) had no effect on behavior, spontaneous motor activity, electroshock- and chemoshock-induced convulsions, hexobarbital sleeping time, pain threshold (mice), conditioned avoidance response (rats) at a dose of 0.4 mg/kg, s.c. "
05/01/1987 - "Chronic administration (5-7 days) of FBM (48 or 95 mg/kg orally) in rats also had no significant effect on either maximal electroshock seizure activity or hexobarbital sleep time. "
05/05/1983 - "On day 28 rats with no convulsions up to day 3 had a marked renewal of tolerance to hexobarbital (29% increase above controls), while rats with convulsions recorded up to day 3 had less or no such tolerance. "
05/05/1983 - "Spontaneous or induced convulsions occurring prior to the hexobarbital threshold determination decreased the tolerance to the same extent (-22 to -28%). "
07/19/1982 - "Tolerance to hexobarbital was found to have a maximum on day 8 in the abstinence while convulsions recorded from the rats participating in the hexobarbital threshold determinations had a maximum on day 14. "
02/01/1962 - "It potentiated the effect of hexobarbitone in mice, produced hypothermia in mice and rats and enhanced leptazol toxicity in rats. "
01/01/1986 - "From the values of cerebral extracellular potassium ion concentration during ischaemia the conclusion might be drawn that hypothermia serves as the principal factor in the protection of the ischaemic brain tissue; meanwhile, also hexobarbital-sodium has a significant though somewhat smaller protective effect."
01/01/1976 - "The administration of this compound together with reserpine reverses central effects of its action (hypothermia, decreased motility, enhancement of hexobarbital activity)."
11/01/1973 - "[Influence of hypothermia on the action, penetration and excretion of hexobarbital and barbital in the rat]."
04/01/1986 - "Inhibition of writhing (60 mg/kg, p.o.), prolongation of hexobarbital-induced hypnosis, hypothermia, antipyretic effect, and inhibition of acetic acid-induced capillary permeability (600 mg/kg, p.o.) in mice were observed after administration of these drugs. "
|4.||Liver Diseases (Liver Disease)
05/01/1992 - "In 260 consecutive patients presenting with a history of liver disease and abnormal laboratory findings but without a current definite diagnosis we have measured the clearance of hexobarbital and investigated if low values in patients are able to support the decision for an invasive diagnostic procedure such as needle biopsy or laparoscopy. "
01/01/1954 - "[The problem of evipan narcosis in liver disease]."
05/01/1982 - "[Compared alteration in paracetamol and hexobarbital metabolism due to liver disease]."
10/01/1989 - "Antipyrine (AP), hexobarbital (HB) and theophylline (TH) were administered simultaneously ('cocktail' design) to 24 patients with various types of liver disease. "
10/01/1989 - "Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach."
04/01/1973 - "[Hexobarbital plasma levels in patients with acute hepatitis during a continuous infusion of hexbarbital]."
10/01/1980 - "Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital. "
06/01/1977 - "[Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)]."
06/01/1977 - "16 patients with acute hepatitis, 18 patients with cirrhosis and a total of 21 volunteers and patients with normal liver function received 7.32 mg/kg hexobarbital by linear intravenous infusion within 60 min. Hexobarbital was determined gaschromatographically in serial blood samples and the hexobarbital-clearance was calculated from the plasma concentration curve versus time. "
03/01/1992 - "It has been established in experiments on 30 day albino rats that in acute hepatitis, the pharmacodynamics of the test drugs hexenal, amidopyrine and ethylmorphine metabolized in the liver is considerably potentiated. "
|5.||barbituric acid (barbiturate)